EU Ruling On Market Exclusivity Period Turns Days Into EURmillions For Drug Companies
This article was originally published in SRA
Just a few days could make a big difference for your company, perhaps millions of Euros. Thanks to a ruling from the Court of Justice of the European Union, some innovative products could have their market exclusivity period extended in some EU markets by a number of days or maybe weeks.
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.